Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
OPERATING EXPENSES:
Research and development	$ 119,039	$ 87,518
General and administrative	59,166	49,401
Total operating expenses	178,205	136,919
LOSS FROM OPERATIONS:	(178,205)	(136,919)
OTHER INCOME (EXPENSE), NET:
Benefit from R&D tax credit	21,097	12,875
Interest income	8,268	4,623
Foreign exchange (losses) gains	(1,032)	3,686
Interest expense	(4,479)	(2,204)
Other income	823	255
Total other income, net	24,677	19,235
Loss before income taxes	(153,528)	(117,684)
Income tax expense	(1,594)	(780)
Net loss	$ (155,122)	$ (118,464)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)	$ (2.30)	$ (2.32)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)	$ (2.30)	$ (2.32)
Weighted average ordinary shares outstanding - basic (in shares)	67,482,902	51,028,024
Weighted average ordinary shares outstanding - diluted (in shares)	67,482,902	51,028,024
Other comprehensive income (loss):
Foreign exchange translation adjustment	$ 732	$ (59)
Comprehensive loss	$ (154,390)	$ (118,523)